The TIMI risk prediction guide predicted mortality in patients with ST-elevation myocardial infarction


**Question**
In patients with ST-elevation myocardial infarction (STEMI), how accurate is the Thrombolysis in Myocardial Infarction (TIMI) risk score for predicting in-hospital, all-cause mortality?

**Design**
The TIMI risk score (developed and validated in several clinical trials) was further evaluated among patients with STEMI from the National Registry of Myocardial Infarction 3 (NRMI 3).

**Setting**
Data for NRMI 3 were collected from 1529 hospitals in the United States.

**Patients**
84 029 patients (mean age 69 y, 59% men) who had STEMI or presumed new left bundle-branch block, completed their stay at the admitting hospital, and were not in cardiogenic shock at the initial evaluation.

**Description of Prediction Guide**
The TIMI risk score for STEMI is a weighted integer score based on 8 clinical risk indicators ascertained at presentation. The risk indicators are age ≥ 75 years (3 points) or 65 to 74 years (2 points); history of diabetes, hypertension, or angina (1 point); systolic blood pressure < 100 mm Hg (3 points); heart rate > 100 beats/min (2 points); Killip class II to IV (2 points); weight < 67 kg (1 point); anterior ST-elevation or left bundle-branch block (1 point); and time to reperfusion therapy > 4 hours (1 point). For each patient, the score is calculated as the arithmetic sum of the points for each risk feature present (range, 0 to 14).

**Main Outcome Measure**
All-cause mortality predicted by using the TIMI risk score.

**Main Results**
In-hospital, all-cause mortality occurred in 12.6% of patients. 48% of patients received reperfusion therapy. An increase in the TIMI risk score from 0 to ≥ 8 points was equivalent to a 30-fold graded increase in risk for all-cause mortality (P < 0.001 for trend). The risk score showed strong prognostic accuracy in the entire NRMI-3 population (area under the receiver-operating characteristic curve [AUROC] = 0.74 vs 0.78 in the derivation set [among patients from the InTime II trial]) and among patients who received acute reperfusion therapy (AUROC = 0.79), who were treated with fibrinolytics (AUROC = 0.79), and who received percutaneous coronary interventions (AUROC = 0.80). Prognostic accuracy for the risk score was low among patients not receiving reperfusion therapy (AUROC = 0.65). The observed mortality rates for patients in NRMI 3 who received reperfusion therapy were strongly correlated with risk estimates from the derivation set of patients (r = 0.99).

**Conclusion**
In patients with ST-elevation myocardial infarction, the Thrombolysis in Myocardial Infarction risk score showed strong prognostic accuracy for predicting all-cause mortality among patients who had been treated with reperfusion therapy.

**Source of funding:** Genentech Inc.

For correspondence: Dr. D.A. Morrow, Brigham and Women’s Hospital, Boston, MA, USA. E-mail damorrow@bics.bwh.harvard.edu.

---

**Major clinical predictors of in-hospital death in patients who receive early reperfusion therapies**

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Adjusted odds ratio (95% CI)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 75 years</td>
<td>5.9 (2.9 to 12.2)</td>
<td>3†</td>
</tr>
<tr>
<td>Killip class II to IV</td>
<td>1.8 (1.2 to 2.8)</td>
<td>2*</td>
</tr>
<tr>
<td>Systolic blood pressure &lt; 100 mm Hg</td>
<td>2.2 (2.0 to 2.4)</td>
<td>5†</td>
</tr>
<tr>
<td>Heart rate &gt; 100 beats/min</td>
<td>1.9 (1.1 to 3.4)</td>
<td>2*</td>
</tr>
<tr>
<td>Any arrhythmia</td>
<td>9.1 (4.3 to 19.2)</td>
<td>3*</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>2.0 (1.7 to 2.3)</td>
<td>6†</td>
</tr>
<tr>
<td>QRS duration &gt; 0.11 sec</td>
<td>7.1 (3.0 to 17.1)</td>
<td>4†</td>
</tr>
<tr>
<td>In-hospital stroke</td>
<td>18.9 (3.3 to 107.2)</td>
<td>3*</td>
</tr>
</tbody>
</table>

*Patients received primary percutaneous revascularization.
†Patients received thrombolytic therapy.

---

**Commentary**
The study by Morrow and colleagues on the TIMI risk score adds little to our current knowledge, much of which is based on the famous classification by Thomas Killip (1) (Table). Most clinicians will probably not formally calculate a risk score in the emergency room or critical care unit. Instead, most will admit patients with STEMI to a critical care setting and appropriately offer efficacious treatments to all. Then they will re-examine whether these therapies are working and pay heed to the items listed in the Table.